- Antikörper-Typ:Primär
- Antigen-Name:RELA proto-oncogene, NF-kB subunit
- Antigen-Symbol:RELA
- Klonalität:Polyklonal
- Konjugation:FITC (Fluorescein Isothiocyanate)
- Wirt:Rabbit
- ImmunoChemie:Yes
- Isotyp:IgG
- Reaktivität:Human,Rat,Mouse
- Kreuzadsorption:No
- Form:liquid
- Gen-ID:5970
- Antigen-Synonyme:nuclear factor NF-kappa-B p65 subunit|v-rel reticuloendotheliosis viral oncogene homolog A|p65|nuclear factor of kappa light polypeptide gene enhancer in B-cells 3|transcription factor p65|v-rel avian reticuloendotheliosis viral oncogene homolog A (nuclear factor of kappa light polypeptide gene enhancer in B-cells 3 (p65))
- Modification:phospho-Thr254
- Lagerungspuffer:Aqueous buffered solution containing 100ug/ml BSA, 50% glycerol and 0.09% sodium azide. Store at 4°C for 12 months.
- Lagertemperatur:Store at 4°C for 12 months
- Konzentration:1 μg/μl
- Transporttemperatur:4°C
- Immunogen:246-257/551
- Reinigung:Purified by Protein A
- VE:100 µl
NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimeric p65-p50 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric p65-p50 and p65-c-Rel complexes are transcriptional activators. The NF-kappa-B p65-p65 complex appears to be involved in invasin-mediated activation of IL-8 expression. The inhibitory effect of I-kappa-B upon NF-kappa-B the cytoplasm is exerted primarily through the interaction with p65. p65 shows a weak DNA-binding site which could contribute directly to DNA binding in the NF-kappa-B complex. Associates with chromatin at the NF-kappa-B promoter region via association with DDX1. Essential for cytokine gene expression in T-cells (PubMed:15790681).
Recommended Dilutions: IF(IHC-P): 1:50-200
Type: Primary
Antigen: RELA
Clonality: Polyclonal
Clone:
Conjugation: FITC (Fluorescein Isothiocyanate)
Epitope:
Host: Rabbit
Isotype: IgG
Reactivity: Human, Mouse, Rat